Non-small cell lung cancer · line 1 · Alectinib monotherapy (ALK+ NSCLC, 1L metastatic OR adjuvant)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	standard
Linked regimen	`REG-ALECTINIB-NSCLC`

ID	`IND-NSCLC-ALK-MET-1L`
Type	Indication
Status	status not declared
Diseases	`DIS-NSCLC`
Sources	`SRC-ESMO-NSCLC-METASTATIC-2024` `SRC-NCCN-NSCLC-2025`

Notes

ALEX: alectinib superior to crizotinib. Lorlatinib (CROWN) more active but toxicity / cognitive AE profile — alectinib remains workhorse 1L; lorlatinib for selected patients.

Used By

Algorithms

ALGO-NSCLC-METASTATIC-1L - ALGO-NSCLC-METASTATIC-1L

Handbook Chapters

HB-NSCLC-METASTATIC-1L - Metastatic NSCLC: driver-first treatment reasoning

Indication

IND-NSCLC-ALK-1L-ENSARTINIB - IND-NSCLC-ALK-1L-ENSARTINIB